NewEdge Advisors LLC Raises Position in Johnson & Johnson $JNJ

Key Points

• NewEdge Advisors increased its Johnson & Johnson stake by 3.4% in the second quarter, bringing its holdings to 917,872 shares valued at approximately $233.1 million. Institutional investors collectively own 69.55% of JNJ.
• Johnson & Johnson exceeded quarterly earnings and revenue expectations, reporting $2.90 EPS and $25.31 billion in revenue, while reaffirming FY 2026 EPS guidance of $11.60–$11.75. The company also pays a quarterly dividend of $1.34 per share, representing a 2.0% yield.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $274.13, although executives have sold shares recently and JNJ trades at a relatively high P/E ratio of about 31.

NewEdge Advisors LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 3.4% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 917,872 shares of the company's stock after purchasing an additional 29,839 shares during the quarter. Johnson & Johnson comprises about 0.7% of NewEdge Advisors LLC's portfolio, making the stock its 26th biggest position. NewEdge Advisors LLC's holdings in Johnson & Johnson were worth $233,112,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in JNJ. Blueline Advisors LLC acquired a new stake in Johnson & Johnson in the fourth quarter worth about $25,000. Outlook Capital Management LLC purchased a new stake in shares of Johnson & Johnson during the second quarter worth about $28,000. MidAtlantic Capital Management Inc. acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at about $37,000. Matrix Trust Co raised its position in shares of Johnson & Johnson by 56.2% in the 2nd quarter. Matrix Trust Co now owns 150 shares of the company's stock valued at $38,000 after purchasing an additional 54 shares during the last quarter. Finally, Hyposwiss Advisors SA purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at approximately $42,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $267.35 on Thursday. The business's 50 day moving average price is $263.25 and its 200 day moving average price is $246.40. The firm has a market cap of $644.28 billion, a P/E ratio of 30.98, a P/E/G ratio of 2.55 and a beta of 0.24. Johnson & Johnson has a 52 week low of $173.33 and a 52 week high of $281.07. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.84 by $0.06. The company had revenue of $25.31 billion during the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. Johnson & Johnson's revenue for the quarter was up 6.6% compared to the same quarter last year. During the same period last year, the firm posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, sell-side analysts expect that Johnson & Johnson will post 11.61 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th were issued a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. The ex-dividend date of this dividend was Tuesday, August 25th. Johnson & Johnson's dividend payout ratio (DPR) is 62.11%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Elizabeth Forminard sold 15,918 shares of Johnson & Johnson stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the transaction, the executive vice president owned 16,994 shares in the company, valued at approximately $4,367,458. This trade represents a 48.37% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Jennifer L. Taubert sold 15,000 shares of the business's stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the transaction, the executive vice president directly owned 194,451 shares of the company's stock, valued at approximately $51,210,615.36. This trade represents a 7.16% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 87,569 shares of company stock valued at $23,064,544. Company insiders own 0.16% of the company's stock.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Promising lung-cancer results strengthen J&J’s growth outlook. New Phase 2b and Phase 3 data showed that RYBREVANT-based combinations for EGFR-mutated non-small-cell lung cancer delivered improved tolerability, fewer treatment-related adverse events and longer reported overall survival. The results could support adoption of RYBREVANT and LAZCLUZE in first-line treatment. Johnson & Johnson Reports Stronger Survival Data in EGFR-Mutated Lung Cancer
• Positive Sentiment: Underlying business momentum remains resilient despite STELARA pressure. Management said sales increased 5.6% excluding the roughly 460-basis-point drag from STELARA, encouraging investors to focus on growth from the broader pharmaceutical and MedTech portfolios. The company previously reported quarterly revenue of $25.31 billion, up 6.6% year over year, and adjusted EPS above consensus. Should You Judge JNJ Stock Without STELARA?
• Positive Sentiment: Potential value creation from a DePuy Synthes sale is attracting investor interest. Apollo Global Management is reportedly considering acquiring J&J’s orthopedics business for close to $20 billion. A transaction could unlock value, sharpen J&J’s portfolio focus and provide capital for acquisitions or shareholder returns, although no deal has been announced. Apollo and J&J Face a High-Stakes Orthopedics Deal
• Neutral Sentiment: J&J remains viewed as a defensive, dividend-oriented healthcare holding. Its roughly 2% yield, recent outperformance and FY 2026 EPS guidance of $11.60–$11.75 support the investment case, but a valuation near 31 times earnings leaves less room for execution disappointments.
• Negative Sentiment: A partnered depression drug failed a key Phase 2 endpoint. Contineum Therapeutics said the MOONLIGHT-1 trial of JNJ-5120/PIPE-307 did not meet its primary efficacy goal in major depressive disorder. J&J is reviewing additional data, but the setback weakens the near-term pipeline contribution from the program. Johnson & Johnson-Partnered Contineum Depression Drug Fails Mid-Stage Trial
• Negative Sentiment: Reported insider activity shows executives have sold shares without any purchases during the past six months, a potentially cautionary sentiment signal, though such transactions may reflect diversification or scheduled sales rather than a fundamental view of JNJ.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on JNJ shares. Guggenheim boosted their target price on shares of Johnson & Johnson from $270.00 to $287.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. Freedom Capital raised shares of Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a report on Thursday, July 16th. Raymond James Financial set a $280.00 price objective on shares of Johnson & Johnson in a research note on Monday, August 3rd. Citigroup boosted their price objective on shares of Johnson & Johnson from $285.00 to $298.00 and gave the company a "buy" rating in a report on Wednesday, July 8th. Finally, Argus set a $300.00 target price on Johnson & Johnson in a research report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $274.13.

Johnson & Johnson Company Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.